Michael Anstey is a Partner at Cambridge Innovation Capital, where they have contributed since 2017. They previously served as a Principal at The Boston Consulting Group from 2010 to 2017 and co-founded Proteorex Therapeutics Inc., which operated from 2014 to 2018. Michael has held several board positions, including with Bicycle Therapeutics and Congenica, and currently serves on multiple boards, including Epitopea and PolyProx Therapeutics Ltd. They hold a DPhil from the University of Oxford and a First Class BSc(Hons) from Queen's University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices